Quinn, David I.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 3,395

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 2,199

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 780

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum

Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., et al. (2003) · Proceedings of the National Academy of Sciences

Gene expression and cancer classificationBreast Cancer Treatment Studies

Cited by 503

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 461

Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

De Bono, J. S., Fong, L., Beer, T. M., Gao, X., Geynisman, D. M., Burris III, H. A., Strauss, J. F., Courtney, K. D., Quinn, D. I., VanderWeele, D. J., et al. (2021) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 39

Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs

Testicular diseases and treatmentsLymphoma Diagnosis and Treatment

Cited by 16

1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Berger, R., Tolcher, A. W., Dorff, T. B., Okubo, S., Abraham, L. S., Reilly, R., Stevenson, C., Wang, S., Arnold, J., Mudd, S. R., et al. (2024) · Annals of Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 8